Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

BioNTech to price vaccine below market rates, differentiate between regions

Published 11/10/2020, 05:27 AM
Updated 11/10/2020, 12:16 PM
© Reuters. FILE PHOTO: The headquarters of German biotech firm BioNTech is photographed in Mainz
PFE
-
BNTX
-

By Ludwig Burger

Frankfurt - BioNTech, first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below "typical market rates" and would differentiate pricing between countries or regions.

Speaking at a Financial Times online event, the German biotech firm's strategy head Ryan Richardson said the price tag of the vaccine, which is co-developed with Pfizer (NYSE:PFE) and which has yet to win regulatory approval, would reflect the financial risks that its private-sector investors have incurred.

"We've tried to pursue a balanced approach that recognises that innovation requires capital and investment so we plan to price our vaccine well below typical market rates reflecting the situation that we're in and with the goal to insure broad-based access around the world," Richardson said at the FT event.

"I expect there to be differential pricing in certain regions of the world," he added, declining to elaborate on the different price tags.

The vaccine was on Monday shown to be 90% effective, based on preliminary trial results, a key milestone in the war against a virus that has killed over a million people and battered the world's economy.

In July Pfizer had agreed with the U.S. government the supply of 100 million doses of its potential vaccine at a price of $39 for a two-dose immunisation, or $19.5 per dose, with the option to sell another 500 million doses under conditions to be negotiated separately.

The European Commission will discuss on Wednesday the adoption of a supply contract with Pfizer and BioNTech. The bloc earlier this week said a contract for up to 300 million doses was close to being signed, without providing financial terms.

Richardson also said that the two partners' goal to supply 1.3 billion doses in 2021 would be the result of a ramping-up efforts well into the second half of next year.

While there would be "significant supply" during the first half, scaling up output would continue throughout 2021.

BioNTech's strategy chief stressed that, even though the German group had received public-sector backing, the risks taken by its investors would merit some financial rewards from a future vaccine.

"We incurred considerable financial risk. We have raised capital in the capital market," he said.

Richard Hatchett, chief executive officer of the Coalition for Epidemic Preparedness Innovations (CEPI), said at the FT event that the Pfizer and BioNTech project was the only one among the 10 leading vaccine developers that had not received "substantial public sector financing".

© Reuters. FILE PHOTO: The headquarters of German biotech firm BioNTech is photographed in Mainz

In June the European Investment Bank, the EU's financial arm, awarded BioNTech 100 million euros in debt financing for its COVID-19 vaccine development and manufacturing.

Germany's research ministry in September granted BioNTech 375 million euros, subject to meeting certain milestones, also to ramp up vaccine development and production.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.